- The surging demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and recombinant proteins, is propelling the mixed mode chromatography resin market. Biopharmaceutical companies are seeking efficient purification techniques to ensure high product purity and yield
- For instance, the increasing production of monoclonal antibodies for therapeutic purposes necessitates robust purification processes, where mixed mode chromatography resins excel in achieving the desired level of product purity and yield, thus driving their market growth
- North America dominated the mixed mode chromatography resin market with the largest revenue share of 32.65% in 2024, driven by the region’s strong pharmaceutical and biotechnology sectors and the increasing demand for efficient purification technologies in biologics manufacturing
- Asia-Pacific mixed mode chromatography resin market is poised to grow at the fastest CAGR of 9.4% during the forecast period of 2025 to 2032, driven by increasing biopharmaceutical production, expanding healthcare infrastructure, and rising investments in biotechnology across countries such as China, Japan, and India
- The Ion Exchange – Hydrophobic segment dominated the mixed mode chromatography resin market with the largest revenue share of 58.7% in 2024, driven by its versatility in capturing a wide range of biomolecules, including antibodies, proteins, and impurities, in a single purification step
